Novo CEO urges staff to embrace more customer-focused culture
Mike Doustdar said Novo will adopt new principles and a new brand as it tries to regain ground from Eli Lilly in obesity drugs.
7 Articles
7 Articles
On Tuesday afternoon, Mike Doustdar presented his and Novo's new direction to the employees. Berlingske was present inside the walls when the CEO pulled off the band-aid and made it clear that the employees must prepare to not only produce medicines for patients, but also consumers.
Novo CEO urges staff to embrace more customer-focused culture - Regional Media News
By Jacob Gronholt-Pedersen COPENHAGEN, Sept 15 (Reuters) - Novo Nordisk's CEO Mike Doustdar on Tuesday urged employees to be more customer-focused, as the Wegovy maker seeks to regain ground in the fast-growing obesity drug market. The push comes as investors question whether Doustdar can restore [...]
The director-president of Novo, Mike Doustdar, charged on Tuesday (15) that the employees have greater focus on the customer, at a time when the manufacturer of the Ozempic seeks to recover space in the accelerated market for anti-obesity medicines. The initiative occurs in the midst of the skepticism of investors about the ability of Doustdar to restore the leadership of the Danish pharmacist, after the company loses space for the American riva…
Novo CEO urges staff to embrace more customer-focused culture
By Jacob Gronholt-Pedersen COPENHAGEN, Sept 15 (Reuters) - Novo Nordisk's CEO Mike Doustdar on Tuesday urged employees to be more customer-focused, as the Wegovy maker seeks to regain ground in the fast-growing obesity drug market. The push comes as ...
Novo Nordisk Shifts Focus in Obesity Drug Battle
Novo Nordisk CEO Mike Doustdar has urged employees to embrace a stronger customer focus as the Danish pharmaceutical giant endeavours to reclaim its leading position in the burgeoning global obesity drug market. Novo Nordisk produces a range of pharmaceutical products, including treatments for diabetes and obesity, notably its popular weight-loss medication, Wegovy. This strategic push
Coverage Details
Bias Distribution
- 80% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
